查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1933132

全球生物列印材料市場預測（至2034年）：按組件、應用、最終用戶和地區分類

Bioprinting Material Market Forecasts to 2034 - Global Analysis By Component (Hydrogels, Extracellular Matrices (ECM), Living Cells, Support Materials/Sacrificial Materials, and Other Biomaterials), Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2026 年，全球生物列印材料市場價值將達到 20.1 億美元，到 2034 年將達到 99.4 億美元，在預測期內的複合年成長率為 22.1%。

生物列印材料市場專注於用於3D列印組織和生物結構的生物墨水、水凝膠、聚合物和細胞相容性材料。該市場為研究實驗室、製藥公司和再生醫學開發商提供支援。成長要素包括組織工程的進步、個人化醫療投資的增加、對替代藥物測試模型的需求、幹細胞研究的進展以及在器官建模、創傷治療和生物醫學研究等領域應用的不斷擴展。

據美國國立衛生研究院 (NIH) 稱，全球每年在再生醫學和組織工程研究方面的投資超過 25 億美元。

利用3D生物列印組織擴大藥物發現與測試的研發

領先的製藥公司正從傳統的2D細胞培養和存在倫理爭議的動物實驗轉向高精度生物列印結構。這些3D模型具有更優異的生理相關性，能夠更精確地進行藥物毒性篩檢和代謝分析。在臨床前階段及早發現潛在的失敗案例，有助於企業大幅降低研發成本並縮短上市時間。這種向先進體外測試的轉變，也確保了對高品質生物墨水和專用生物列印材料的持續需求。

生物墨水和活細胞研究成本過高

開發能夠在結構完整性和生物活性之間保持微妙平衡的生物墨水，需要複雜的化學成分和嚴格的純化過程。此外，取得和維持特定的人類原代細胞和幹細胞會顯著增加研究預算的開支。對於許多學術機構和小規模生技公司而言，這些持續的支出構成了限制，並減緩了實驗檢驗的步伐。這種經濟壓力往往將生物列印技術的應用限制在高預算計劃中，阻礙了其在眾多對價格敏感的醫療領域的廣泛商業化應用。

化妝品檢測與個人化醫療

隨著國際社會對化妝品動物試驗的禁令不斷擴大，化妝品產業正轉向生物列印皮膚模型來評估成分的安全性和有效性。同時，個人化醫療的興起為利用患者自身細胞列印客製化組織移植物和晶片器官模型提供了一個獨特的細分市場。這些客製化解決方案最大限度地降低了移植排斥的風險，並實現了個人化的藥物敏感性測試。此類應用蘊藏著巨大的未開發收入來源，並有可能重新定義標準的臨床和工業實踐。

大規模生產的可擴展性和可重複性有限

生物列印本質上是一個高精度、耗時的過程，且面臨產量限制。確保所有生物列印構建體在大規模批量生產中保持相同的細胞分佈和結構密度是一項技術挑戰。不同批次材料的差異以及環境條件的變化會導致結果的變異性，這對於臨床應用而言是不可接受的。如果自動化品管和高速多噴頭列印技術沒有突破性進展，生物列印產業將面臨淪為小眾研究工具而非再生醫學標準生產方法的風險。

新冠疫情的影響：

新冠疫情為生物列印材料市場帶來了挑戰和機會。供應鏈中斷和實驗室關閉最初阻礙了常規研究活動。然而，這場危機加速了生物列印技術在疫苗研發和呼吸系統疾病建模的應用。研究人員利用3D生物列印的肺組織，在可控的、與人體相關的環境中闡明病毒感染機制並評估抗病毒效果。這種快速轉變證明了該技術在醫療應變方面的有效性，並促使政府和私人投資者投入大量資金，以支持其在疫情後的發展。

預計在預測期內，水凝膠細分市場將佔據最大的市場佔有率。

由於水凝膠作為活細胞結構支架的重要作用，預計在預測期內，水凝膠細分市場將佔據最大的市場佔有率。水凝膠因其高含水量和生物相容性而備受青睞，這使其能夠高度模擬人體組織的天然細胞外基質。水凝膠的多功能性使其能夠與各種生長因子和訊號分子結合，從而促進細胞增殖和分化。此外，能夠響應熱或化學刺激的「智慧」水凝膠的開發，進一步拓展了其應用範圍。

預計在預測期內，生物製藥和生技公司板塊的複合年成長率將最高。

預計在預測期內，生物製藥和生技公司板塊將呈現最高的成長率，因為這些公司正積極將生物列印技術整合到其研發開發平臺中。對更有效率藥物開發流程的需求正推動這些公司大力投資於3D細胞培養系統，該系統能夠提供比傳統方法更準確的預測數據。此外，生物列印材料供應商與生物技術公司之間的策略合作也日益普遍，旨在為腫瘤學和神經病學等特定治療領域開發專有生物墨水。全球對個人化治療方案和再生醫學日益成長的需求，進一步推動了該板塊的快速擴張。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。這主要得益於該地區先進的醫療保健基礎設施和對生命科學領域的巨額投資。美國和加拿大擁有眾多產業巨頭和頂尖研究型大學，為技術創新建立了強大的生態系統。此外，有利的法規結構和對先進醫療技術的早期應用也為其帶來了競爭優勢。該地區對再生醫學的重視以及慢性病的高發生率，促使生物列印組織解決方案的開發勢在必行，這將確保北美繼續在全球市場保持重要的收入來源地位。

年複合成長率最高的地區：

由於生物技術的快速發展和政府對醫學研究支持力度的加大，預計亞太地區在預測期內將實現最高的複合年成長率。中國、印度和日本等國正大力投資醫療現代化和醫療設備製造的本土化。該地區日益老化的人口以及慢性病的不斷增多，催生了對創新器官和組織替代療法的巨大需求。此外，臨床試驗成本低廉且監管透明度的提高，也促使全球生物列印公司在亞洲拓展業務，從而推動了前所未有的市場成長。

免費客製化服務資訊：

購買此報告後，您將獲得以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測以及複合年成長率（註：可行性需確認）。
  • 競爭標竿分析
    • 基於產品系列、地域覆蓋範圍和策略聯盟對主要參與者進行基準分析

目錄

第1章執行摘要

第2章 前言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球生物列印材料市場（按成分分類）

  • 水凝膠
    • 天然水凝膠
    • 合成水凝膠
    • 混合/水凝膠複合材料
  • 細胞外基質（ECM）
  • 活細胞
  • 輔助/犧牲材料
  • 其他生物材料

6. 全球生物列印材料市場（按應用分類）

  • 組織工程與再生醫學
    • 骨/軟骨
    • 皮膚及覆蓋組織
    • 血管和心臟
    • 神經
    • 其他組織
  • 藥物發現與開發
  • 癌症研究
  • 牙科應用
  • 化妝品和皮膚護理
  • 其他用途

7. 全球生物列印材料市場（依最終用戶分類）

  • 研究和學術機構
  • 生物製藥和生物技術公司
  • 醫院和診斷中心
  • 受託研究機構（CRO）
  • 其他最終用戶

8. 全球生物列印材料市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：企業概況

  • CELLINK AB
  • Advanced BioMatrix, Inc.
  • CollPlant Biotechnologies Ltd.
  • Organovo Holdings, Inc.
  • 3D Systems, Inc.
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Corning Incorporated
  • Lonza Group AG
  • FUJIFILM Corporation
  • Bio-Techne Corporation
  • Aspect Biosystems Ltd.
  • Gelita AG
  • Rousselot BV
Product Code: SMRC33700

According to Stratistics MRC, the Global Bioprinting Material Market is accounted for $2.01 billion in 2026 and is expected to reach $9.94 billion by 2034 growing at a CAGR of 22.1% during the forecast period. The bioprinting material market focuses on bioinks, hydrogels, polymers, and cell-compatible materials used in 3D printing tissues and biological structures. It supports research laboratories, pharmaceutical companies, and regenerative medicine developers. Growth is driven by advances in tissue engineering, increasing investment in personalized medicine, demand for alternative drug-testing models, progress in stem cell research, and expanding applications in organ modeling, wound healing, and biomedical research.

According to the U.S. National Institutes of Health (NIH), more than USD 2.5 billion annually is invested globally in regenerative medicine and tissue engineering research.

Market Dynamics:

Driver:

Growing R&D in drug discovery and testing using 3D bioprinted tissues

Pharmaceutical giants are increasingly transitioning from traditional 2D cell cultures and ethically sensitive animal testing toward high-fidelity bioprinted constructs. These 3D models offer superior physiological relevance, allowing for more accurate toxicity screening and metabolic profiling of drug candidates. By identifying potential failures earlier in the preclinical phase, companies significantly reduce development costs and time-to-market. This shift toward advanced in vitro testing ensures a sustained demand for high-quality bioinks and specialized bioprinting materials.

Restraint:

Extremely high cost of research-grade bioinks and living cells

Developing bioinks that maintain the delicate balance between structural integrity and biological viability requires complex chemical formulations and rigorous purification processes. Additionally, the procurement and maintenance of specific human primary cells and stem cells add substantial overhead to research budgets. For many academic institutions and smaller biotechnology startups, these recurring expenses can be restrictive, slowing the pace of experimental validation. This financial pressure often limits the use of bioprinting to high-budget projects, hindering broader commercialization across various price-sensitive medical sectors.

Opportunity:

Expansion into cosmetic testing and personalized medicine

With increasing global bans on animal testing for beauty products, the cosmetic industry is turning to bioprinted skin models to evaluate ingredient safety and efficacy. Simultaneously, the rise of personalized medicine offers a unique niche where patient-derived cells are used to print custom tissue grafts and organ-on-a-chip models. These tailored solutions minimize the risk of transplant rejection and allow for individualized drug sensitivity testing. Such applications represent a massive, untapped revenue stream that could redefine standard clinical and industrial practices.

Threat:

Limited scalability and reproducibility for mass production

Bioprinting is inherently a high-precision, time-intensive process that struggles with throughput limitations. Ensuring that every bioprinted construct maintains identical cellular distribution and structural density across large batches is technically challenging. Variations in material batches or environmental conditions can lead to inconsistent results, which is unacceptable for clinical-grade applications. Without significant breakthroughs in automated quality control and high-speed multi-nozzle printing technologies, the industry risks remaining a niche research tool rather than a standard manufacturing method for regenerative medicine.

Covid-19 Impact:

The COVID-19 pandemic presented both challenges and opportunities for the bioprinting material market. Initially, disruptions in the supply chain and laboratory closures impeded standard research activities. However, the crisis expedited the implementation of bioprinting for vaccine development and respiratory disease modeling. Researchers employed 3D bioprinted lung tissues to investigate viral infection mechanisms and evaluate antiviral efficacy in a controlled, human-relevant setting. This urgent transition underscored the technology's efficacy in emergency medical response, consequently drawing substantial government funding and private investment that has supported post-pandemic expansion.

The hydrogels segment is expected to be the largest during the forecast period

The hydrogels segment is expected to account for the largest market share during the forecast period due to its indispensable role as a structural scaffold for living cells. Hydrogels are favored for their high water content and biocompatibility, which closely mimic the natural extracellular matrix of human tissues. Their versatility allows for the incorporation of various growth factors and signaling molecules, facilitating cell proliferation and differentiation. Furthermore, the development of "smart" hydrogels that respond to thermal or chemical stimuli has broadened their application scope.

The biopharmaceutical & biotechnology companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biopharmaceutical & biotechnology companies segment is predicted to witness the highest growth rate as these entities aggressively integrate bioprinting into their discovery pipelines. The push for more efficient drug development processes is driving these companies to invest heavily in 3D cell culture systems that provide better predictive data than traditional methods. Moreover, strategic collaborations between bioprinting material providers and biotech firms are becoming commonplace, aimed at developing proprietary bioinks for specific therapeutic areas like oncology and neurology. The rising global demand for personalized therapeutic solutions and regenerative medicine further fuels this segment's rapid expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, primarily driven by its sophisticated healthcare infrastructure and substantial investment in life sciences. The presence of major industry players and leading research universities in the United States and Canada fosters a robust ecosystem for technological innovation. Additionally, favorable regulatory frameworks and the early adoption of advanced medical technologies provide a competitive edge. The region's focus on regenerative medicine and the high prevalence of chronic diseases necessitate the development of bioprinted tissue solutions, ensuring North America remains the primary revenue generator for the global market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR due to rapid advancements in biotechnology and increased government support for medical research. Countries like China, India, and Japan are investing heavily in healthcare modernization and the indigenization of medical device manufacturing. The growing geriatric population in this region, coupled with a rise in chronic conditions, is creating a massive demand for innovative organ and tissue replacement therapies. Furthermore, lower clinical trial costs and improving regulatory clarity are attracting global bioprinting companies to expand their footprint in Asia, leading to an unprecedented rate of market growth.

Key players in the market

Some of the key players in Bioprinting Material Market include CELLINK AB, Advanced BioMatrix, Inc., CollPlant Biotechnologies Ltd., Organovo Holdings, Inc., 3D Systems, Inc., Merck KGaA, Thermo Fisher Scientific Inc., Sartorius AG, Corning Incorporated, Lonza Group AG, FUJIFILM Corporation, Bio-Techne Corporation, Aspect Biosystems Ltd., Gelita AG, and Rousselot B.V.

Key Developments:

In December 2025, CELLINK (BICO Group) unveiled a new bioink portfolio designed for vascularized tissue printing, targeting pharmaceutical R&D.

In October 2025, Organovo announced progress in 3D-printed liver tissue models, expanding its bioprinting material applications for drug testing.

In August 2025, 3D Systems launched collagen-based bioprinting materials, strengthening its healthcare additive manufacturing division.

Components Covered:

  • Hydrogels
  • Extracellular Matrices (ECM)
  • Living Cells
  • Support Materials/Sacrificial Materials
  • Other Biomaterials

Applications Covered:

  • Tissue Engineering & Regenerative Medicine
  • Drug Discovery & Development
  • Cancer Research
  • Dental Applications
  • Cosmetic & Dermal Applications
  • Other Applications

End Users Covered:

  • Research & Academic Institutions
  • Biopharmaceutical & Biotechnology Companies
  • Hospitals & Diagnostic Centers
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bioprinting Material Market, By Component

  • 5.2 Hydrogels
    • 5.2.1 Natural Hydrogels
    • 5.2.2 Synthetic Hydrogels
    • 5.2.3 Hybrid/Hydrogel Composites
  • 5.3 Extracellular Matrices (ECM)
  • 5.4 Living Cells
  • 5.5 Support Materials/Sacrificial Materials
  • 5.6 Other Biomaterials

6 Global Bioprinting Material Market, By Application

  • 6.1 Introduction
  • 6.2 Tissue Engineering & Regenerative Medicine
    • 6.2.1 Bone & Cartilage
    • 6.2.2 Skin & Integumentary
    • 6.2.3 Vascular & Cardiac
    • 6.2.4 Neural
    • 6.2.5 Other Tissues
  • 6.3 Drug Discovery & Development
  • 6.4 Cancer Research
  • 6.5 Dental Applications
  • 6.6 Cosmetic & Dermal Applications
  • 6.7 Other Applications

7 Global Bioprinting Material Market, By End User

  • 7.1 Introduction
  • 7.2 Research & Academic Institutions
  • 7.3 Biopharmaceutical & Biotechnology Companies
  • 7.4 Hospitals & Diagnostic Centers
  • 7.5 Contract Research Organizations (CROs)
  • 7.6 Other End Users

8 Global Bioprinting Material Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 CELLINK AB
  • 10.2 Advanced BioMatrix, Inc.
  • 10.3 CollPlant Biotechnologies Ltd.
  • 10.4 Organovo Holdings, Inc.
  • 10.5 3D Systems, Inc.
  • 10.6 Merck KGaA
  • 10.7 Thermo Fisher Scientific Inc.
  • 10.8 Sartorius AG
  • 10.9 Corning Incorporated
  • 10.10 Lonza Group AG
  • 10.11 FUJIFILM Corporation
  • 10.12 Bio-Techne Corporation
  • 10.13 Aspect Biosystems Ltd.
  • 10.14 Gelita AG
  • 10.15 Rousselot B.V.

List of Tables

  • Table 1 Global Bioprinting Material Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Bioprinting Material Market Outlook, By Component (2023-2034) ($MN)
  • Table 3 Global Bioprinting Material Market Outlook, By Hydrogels (2023-2034) ($MN)
  • Table 4 Global Bioprinting Material Market Outlook, By Natural Hydrogels (2023-2034) ($MN)
  • Table 5 Global Bioprinting Material Market Outlook, By Synthetic Hydrogels (2023-2034) ($MN)
  • Table 6 Global Bioprinting Material Market Outlook, By Hybrid / Hydrogel Composites (2023-2034) ($MN)
  • Table 7 Global Bioprinting Material Market Outlook, By Extracellular Matrices (ECM) (2023-2034) ($MN)
  • Table 8 Global Bioprinting Material Market Outlook, By Living Cells (2023-2034) ($MN)
  • Table 9 Global Bioprinting Material Market Outlook, By Support / Sacrificial Materials (2023-2034) ($MN)
  • Table 10 Global Bioprinting Material Market Outlook, By Other Biomaterials (2023-2034) ($MN)
  • Table 11 Global Bioprinting Material Market Outlook, By Application (2023-2034) ($MN)
  • Table 12 Global Bioprinting Material Market Outlook, By Tissue Engineering & Regenerative Medicine (2023-2034) ($MN)
  • Table 13 Global Bioprinting Material Market Outlook, By Bone & Cartilage (2023-2034) ($MN)
  • Table 14 Global Bioprinting Material Market Outlook, By Skin & Integumentary (2023-2034) ($MN)
  • Table 15 Global Bioprinting Material Market Outlook, By Vascular & Cardiac (2023-2034) ($MN)
  • Table 16 Global Bioprinting Material Market Outlook, By Neural (2023-2034) ($MN)
  • Table 17 Global Bioprinting Material Market Outlook, By Other Tissues (2023-2034) ($MN)
  • Table 18 Global Bioprinting Material Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
  • Table 19 Global Bioprinting Material Market Outlook, By Cancer Research (2023-2034) ($MN)
  • Table 20 Global Bioprinting Material Market Outlook, By Dental Applications (2023-2034) ($MN)
  • Table 21 Global Bioprinting Material Market Outlook, By Cosmetic & Dermal Applications (2023-2034) ($MN)
  • Table 22 Global Bioprinting Material Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 23 Global Bioprinting Material Market Outlook, By End User (2023-2034) ($MN)
  • Table 24 Global Bioprinting Material Market Outlook, By Research & Academic Institutions (2023-2034) ($MN)
  • Table 25 Global Bioprinting Material Market Outlook, By Biopharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 26 Global Bioprinting Material Market Outlook, By Hospitals & Diagnostic Centers (2023-2034) ($MN)
  • Table 27 Global Bioprinting Material Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 28 Global Bioprinting Material Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.